CGON vs CAI
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CGON · CG Oncology$75.99 ▲ 17.27%
CAI · Caris Life Sciences$25.23 ▼ 3.07%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CGON +88.9%
- CAI +1.7%
Head to head
| Metric | CGON | CAI |
|---|---|---|
| Price | $75.99 | $25.23 |
| Change today | ▲ 17.27% | ▼ 3.07% |
| Market cap | $6.74B | $7.24B |
| Return, 3 months | -0.7% | +7.8% |
| Return, year to date | +83.0% | -6.5% |
| Return, 1 year | +91.5% | -1.5% |
| P/E (TTM) | – | 75.3 |
| P/B | 6.8 | 11.3 |
| P/E percentile vs own 5y | 64th | 99th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +45.4% |
| Net profit growth (YoY) | -90.8% | +99.1% |
| Gross margin | -85.2% | 69.7% |
| Operating margin | -4,056.2% | 15.5% |
| Net margin | -3,602.7% | 10.6% |
| Return on equity | -26.4% | 20.1% |
| Analyst target vs. price | +21.8% | +22.9% |
| Analyst buy share | 100% | 75% |
| RSI (14) | 68 | 35 |
| 30-day volatility | 63.7% | 96.1% |
| Max drawdown, 1 year | -27.4% | -53.3% |
| Trend read | Strong uptrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CAI is the largest of the group by market value.
- CGON has returned the most over the past year.
- CAI keeps the most profit per dollar of sales.
- CGON has been the calmest stock over the last 30 days.